COVAX
Gavi co-led COVAX, the vaccines pillar of the Access to COVID-19 Tools Accelerator (ACT-A).
About
From 2020 through 2023, COVAX, a global initiative focused on equitable access to COVID-19 vaccines, enabled the largest and fastest public health roll-out in history in the face of an unprecedented global emergency. It helped avert millions of deaths and generated invaluable learnings that underscore how the world must be better prepared for future pandemics.
Click below for COVAX’s impact, history, key learnings and participant perspectives.
Gavi's role in COVAX
Managing the end-to-end coordination of COVAX, ensuring pooled procurement and equitable distribution of COVID-19 vaccines around the world.
The Gavi COVAX Advance Market Commitment (AMC) ensured access to COVID-19 vaccines and support for lower-income countries.
COVAX in humanitarian settings
Addressing the most unpredictable and hard-to-fill gaps in access.
COVID-19 vaccines FAQ
Now that COVID-19 vaccines have reached billions of people worldwide, the evidence is overwhelming that no matter which one you take, the vaccines offer life-saving protection against a disease that has killed millions.
Latest news
Novavax and Gavi Reach Settlement on 2021 COVID-19 Vaccine Advance Purchase Agreement
Novavax, Inc. (Nasdaq: NVAX) and Gavi, the Vaccine Alliance (Gavi) today announced they have reached a settlement related to the 2021 Advance Purchase Agreement (APA) for Novavax’s prototype COVID-19 vaccine (NVX-CoV2373). This agreement brings…
COVID-19 vaccinations shift to regular immunisation as COVAX draws to a close
COVAX will close 31 December 2023 having delivered nearly 2 billion doses of vaccines to 146 economies, and averted an estimated 2.7 million deaths in AMC lower-income participating economies.
Gavi and Moderna agree to cancel remaining volumes under existing COVAX supply agreement.
Explore COVAX
A historic multilateral effort co-led by Gavi, CEPI, WHO and UNICEF from 2020 through 2023, COVAX pushed to centre vaccine equity at the heart of the global response to the COVID-19 pandemic. COVAX will come to a close on 31 December 2023.
Managing the end-to-end coordination of COVAX, ensuring pooled procurement and equitable distribution of COVID-19 vaccines around the world.
The Gavi COVAX Advance Market Commitment (AMC) ensured access to COVID-19 vaccines and support for lower-income countries.
COVAX in humanitarian settings
Addressing the most unpredictable and hard-to-fill gaps in access.